Karyopharm Therapeutics Inc (OQ:KPTI)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 85 Wells Ave
NEWTON CENTER MA 02459-3298
Tel: N/A
Website: https://karyopharm.com
IR: See website
<
Key People
Sharon Shacham
President, Chief Scientific Officer
Michael G. Kauffman
Co-Founder, Chief Executive Officer and Director
Michael P. Mason
Chief Financial Officer, Senior Vice President, Treasurer
Christopher B. Primiano
Executive Vice President, Chief Business Officer, General Counsel and Secretary
Perry Monaco
Senior Vice President of Sales
Ran Frenkel
Chief Development Operations Officer
Business Overview
Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
Financial Overview
For the three months ended 31 March 2019, Karyopharm Therapeutics Inc revenues decreased 98% to $155K. Net loss increased 72% to $66.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and Administrative increase from $7.6M to $27.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.78 to -$1.09.
Employees: 332 as of Feb 15, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $345.12M as of Mar 31, 2019
Annual revenue (TTM): $20.49M as of Mar 31, 2019
EBITDA (TTM): -$205.05M as of Mar 31, 2019
Net annual income (TTM): -$206.11M as of Mar 31, 2019
Free cash flow (TTM): -$193.12M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 60,864,445 as of Apr 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization